PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
This article was originally published in The Tan Sheet
Executive Summary
An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.
You may also be interested in...
Official PPA Removal From Market Sought In FDA Proposed Rule
FDA would "assure the removal" of OTC drugs containing phenylpropanolamine (PPA) from the market and "prohibit future marketing of such products" under a proposed rule published in the Federal Register Dec. 22
Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA
LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations
Ephedra Marketing, Availability Debated At Government Reform Hearing
FDA's Center for Food Safety & Applied Nutrition has reached a standoff with industry over how best to regulate ephedrine alkaloid-containing dietary supplements, CFSAN Director Joseph Levitt stated during a House Government Reform Committee hearing on supplement regulation March 20.